Please try another search
Phase 1 Clinical Trial Timelines Significantly AcceleratedTop-Line Data Readout from Single Ascending Dose Part 1 Now Expected in the Third Quarter of 2024First Patient Dosed in the Multiple Ascending...
CAMBRIDGE, Mass. - NeuroBo Pharmaceuticals, Inc. (NASDAQ: NASDAQ:NRBO) has announced the completion of the first part of its Phase 2a clinical trial for DA-1241, a novel treatment candidate for...
Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in ObesityPhase 1 Trial of DA-1726 Expected to Dose First Patient in Second Quarter of...
Instrument Type
Region
Sector
Industry
Date
Category
Provider